Figure S5 from Combination Therapy with NHS-muIL12 and Avelumab (anti-PD-L1) Enhances Antitumor Efficacy in Preclinical Cancer Models

Authors :: Yan Lan
Laszlo Radvanyi
Jessie M. English
Kin-Ming Lo
Robert Tighe
Huakui Yu
Hong Wang
Jin Qi
Guozhong Qin
Bo Marelli
Giorgio Kradjian
Wilson Guzman
Vivian M. Hernández
P. Alexander Rolfe
Yanping Zhang
Chunxiao Xu
Publication Year :: 2023
Publisher :: American Association for Cancer Research (AACR), 2023.
Abstract: NHS-muIL12 and avelumab combination treatment enhanced the necrotic fraction in EMT-6 tumors.

Full Text Access

Tools